Carter Charles Ross 4

What Happened
Carter Charles Ross, Chief Financial Officer of Ovid Therapeutics, received a grant of 50,000 restricted stock units (RSUs) on July 6, 2026. The reported acquisition price is $0.00 (an award), so no cash was paid by the insider at grant. Each RSU represents a contingent right to one share of Ovid common stock.

Key Details

• Transaction date: July 6, 2026; Filing date: July 8, 2026 (filed within the Form 4 reporting window).
• Transaction type/code: A — Award/Grant of RSUs. Reported acquisition price: $0.00.
• Shares granted: 50,000 RSUs. Reported post-transaction beneficial ownership: not specified in the provided data.
• Vesting: RSUs vest in two equal annual installments commencing July 6, 2027, subject to continuous service (per footnote).
• Footnotes: F1 = RSU award with the stated vesting schedule; F2 = each RSU converts to one share of common stock when settled. No 10b5-1 plan, tax withholding, or sale reported.

Context
RSU awards are compensation rather than open-market purchases or sales; they do not involve immediate cash outlay or sale proceeds and typically vest over time. This grant increases Ross’s potential future ownership if vesting conditions are met, but it does not by itself indicate current buying or selling intent.